13.75
price up icon3.31%   0.44
after-market Dopo l'orario di chiusura: 13.75
loading

Generate Biomedicines Inc Borsa (GENB) Ultime notizie

pulisher
Apr 03, 2026

Top Generate Biomedicines (GENB) Competitors 2026 - marketbeat.com

Apr 03, 2026
pulisher
Apr 02, 2026

Cantor Fitzgerald reiterates Generate Biomedicines stock rating By Investing.com - Investing.com Canada

Apr 02, 2026
pulisher
Mar 30, 2026

IPO Tracker 2026: Biotech Mega-Rounder Kailera Seeks IPO - BioSpace

Mar 30, 2026
pulisher
Mar 27, 2026

Kailera Therapeutics files for US IPO - MarketScreener

Mar 27, 2026
pulisher
Mar 27, 2026

Flagship-backed Generate Bio seeks $425 million in US IPO - MSN

Mar 27, 2026
pulisher
Mar 27, 2026

Generate Biomedicines (NASDAQ:GENB) Rating Increased to Hold at Zacks Research - marketbeat.com

Mar 27, 2026
pulisher
Mar 26, 2026

Generate Biomedicines, Inc.Common Stock (Nasdaq:GENB) Stock Quote - FinancialContent

Mar 26, 2026
pulisher
Mar 25, 2026

This KB Home Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tuesday - Sahm

Mar 25, 2026
pulisher
Mar 24, 2026

Generate Biomedicines gains buy initiations from Guggenheim, Piper Sandler - Seeking Alpha

Mar 24, 2026
pulisher
Mar 24, 2026

The Goldman Sachs Group Initiates Coverage on Generate Biomedicines (NASDAQ:GENB) - MarketBeat

Mar 24, 2026
pulisher
Mar 24, 2026

Morgan Stanley Initiates Coverage on Generate Biomedicines (NASDAQ:GENB) - marketbeat.com

Mar 24, 2026
pulisher
Mar 24, 2026

Generate Biomedicines (NASDAQ:GENB) Coverage Initiated at Guggenheim - marketbeat.com

Mar 24, 2026
pulisher
Mar 24, 2026

Generate Biomedicines (NASDAQ:GENB) Earns Overweight Rating from Analysts at Cantor Fitzgerald - MarketBeat

Mar 24, 2026
pulisher
Mar 24, 2026

Goldman Sachs Initiates Coverage on Generate Biomedicines With Buy Rating, $26 Price Target - MarketScreener

Mar 24, 2026
pulisher
Mar 24, 2026

Guggenheim Initiates Coverage on Generate Biomedicines With Buy Rating, $30 Price Target - marketscreener.com

Mar 24, 2026
pulisher
Mar 24, 2026

Piper Sandler initiates Generate Biomedicines stock at overweight By Investing.com - Investing.com Canada

Mar 24, 2026
pulisher
Mar 24, 2026

Morgan Stanley Initiates Generate Biomedicines at Overweight With $20 Price Target - marketscreener.com

Mar 24, 2026
pulisher
Mar 24, 2026

Morgan Stanley initiates Generate Biomedicines stock at overweight By Investing.com - Investing.com Canada

Mar 24, 2026
pulisher
Mar 24, 2026

Piper Sandler initiates Generate Biomedicines stock at overweight - Investing.com

Mar 24, 2026
pulisher
Mar 24, 2026

Morgan Stanley initiates Generate Biomedicines stock at overweight - Investing.com

Mar 24, 2026
pulisher
Mar 24, 2026

Goldman Sachs initiates Generate Biomedicines stock with buy rating on AI platform potential - Investing.com

Mar 24, 2026
pulisher
Mar 24, 2026

Guggenheim initiates Generate Biomedicines stock with buy rating By Investing.com - Investing.com Australia

Mar 24, 2026
pulisher
Mar 24, 2026

Guggenheim initiates Generate Biomedicines stock with buy rating - investing.com

Mar 24, 2026
pulisher
Mar 22, 2026

ETFs Investing in Generate Biomedicines, Inc. Stocks - TradingView

Mar 22, 2026
pulisher
Mar 19, 2026

Generate Biomedicines IPO Turns Heads - Yahoo! Finance Canada

Mar 19, 2026
pulisher
Mar 18, 2026

Generate Biomedicines (GENB) Stock Trends and Sentiment 2026 - MarketBeat

Mar 18, 2026
pulisher
Mar 17, 2026

Free cash flow per share of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView

Mar 17, 2026
pulisher
Mar 17, 2026

GENB | Generate Biomedicines, Inc. Common Stock Data, Price & News - Quiver Quantitative

Mar 17, 2026
pulisher
Mar 17, 2026

Total debt per share of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView

Mar 17, 2026
pulisher
Mar 17, 2026

Book value per share of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView

Mar 17, 2026
pulisher
Mar 17, 2026

Revenue per share of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView

Mar 17, 2026
pulisher
Mar 17, 2026

Generate Biomedicines (GENB) 10K Form and SEC Filings 2026 - MarketBeat

Mar 17, 2026
pulisher
Mar 16, 2026

Total liabilities & shareholders' equities of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView

Mar 16, 2026
pulisher
Mar 16, 2026

After tax other income/expense of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView

Mar 16, 2026
pulisher
Mar 16, 2026

Gross profit of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView

Mar 16, 2026
pulisher
Mar 16, 2026

EBIT of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView

Mar 16, 2026
pulisher
Mar 16, 2026

Total revenue of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView

Mar 16, 2026
pulisher
Mar 16, 2026

Average basic shares outstanding of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView

Mar 16, 2026
pulisher
Mar 16, 2026

Cash per share of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView

Mar 16, 2026
pulisher
Mar 16, 2026

Pretax income of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView

Mar 16, 2026
pulisher
Mar 16, 2026

Generate Biomedicines, Inc. Income Statement – NASDAQ:GENB - TradingView

Mar 16, 2026
pulisher
Mar 16, 2026

Generate Biomedicines, Inc. Dividends – NASDAQ:GENB - TradingView

Mar 16, 2026
pulisher
Mar 16, 2026

Net debt of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView

Mar 16, 2026
pulisher
Mar 16, 2026

Tangible book value per share of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView

Mar 16, 2026
pulisher
Mar 15, 2026

Cash from investing activities of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView

Mar 15, 2026
pulisher
Mar 15, 2026

Free cash flow of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView

Mar 15, 2026
pulisher
Mar 15, 2026

Generate Biomedicines, Inc. Cash Flow – NASDAQ:GENB - TradingView

Mar 15, 2026
pulisher
Mar 15, 2026

Long term debt to total assets ratio of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView

Mar 15, 2026
pulisher
Mar 15, 2026

Total liabilities of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView

Mar 15, 2026
pulisher
Mar 15, 2026

Enterprise value to EBITDA ratio of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView

Mar 15, 2026
pulisher
Mar 14, 2026

Price to sales ratio of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView

Mar 14, 2026
pulisher
Mar 14, 2026

GENB News Today | Why did Generate Biomedicines stock go down today? - MarketBeat

Mar 14, 2026
pulisher
Mar 14, 2026

Working capital per share of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView

Mar 14, 2026
pulisher
Mar 14, 2026

Generate Biomedicines (GENB) Stock Price, News & Analysis - MarketBeat

Mar 14, 2026
pulisher
Mar 14, 2026

Generate Biomedicines (NASDAQ:GENB) Upgraded by Wall Street Zen to "Hold" Rating - MarketBeat

Mar 14, 2026
$99.12
price up icon 0.49%
$28.33
price up icon 1.76%
$48.57
price up icon 0.16%
$91.18
price up icon 1.97%
ONC ONC
$310.79
price up icon 0.76%
$162.43
price down icon 1.47%
Capitalizzazione:     |  Volume (24 ore):